Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Quince Therapeutics, Inc. (QNCX)
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 beginning at 7 a.m. Eastern Time.A webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com.About Quince TherapeuticsQuince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, X, and YouTube.View source version on
Show less
Read more
Impact Snapshot
Event Time:
QNCX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNCX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNCX alerts
High impacting Quince Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
QNCX
News
- Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsBusiness Wire
- Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchBusiness Wire
- Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual MeetingBusiness Wire
- Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Quince Therapeutics, Inc. (NASDAQ: QNCX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
QNCX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- 11/13/24 - Form SC
- QNCX's page on the SEC website